Filing Flows › Zymeworks (ZYME) › Q3 2026 › vs Q2 2026
Zymeworks (ZYME) Q3 2026 vs Q2 2026 (quarter over quarter)
Zymeworks's revenue rose $252M (56×) from $4.6M in Q2 2026 to $256M in Q3 2026. Operating margin 69.2% against -919.0% (+988.2 pts).
Zymeworks, Q3 2026: revenue $256M (+829% year over year), operating margin 69.2%, net earnings $174M, operating cash flow −$24.0M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 69.2% | -919.0% | +988.2 pts |
| Net margin | 67.7% | -980.8% | +1048.5 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $256M | $4.6M | $252M | 56× |
| Operating profit | $178M | −$42.2M | $220M | — |
| Costs & expenses | $78.9M | $46.8M | $32.1M | +69% |
| Pre-tax earnings | $173M | −$45.3M | $219M | — |
| Other expense, net | $4.3M | $3.1M | $1.2M | +40% |
| Research & development | $36.1M | $27.4M | $8.7M | +32% |
| Income tax benefit | $452K | $273K | $179K | +66% |
| Net earnings | $174M | −$45.0M | $219M | — |
| Operating cash sources | $223M | −$604K | $223M | — |
| Depreciation & amortization | $1.7M | $1.1M | $584K | +52% |
| Share-based compensation | $23.1M | $11.3M | $11.7M | +104% |
| Cash used in operations | $24.0M | $31.9M | −$7.9M | -25% |
| Working capital & other | $223M | −$604K | $223M | — |
Questions
How much did Zymeworks's revenue grow quarter over quarter in Q3 2026?
Zymeworks's revenue rose $252M (56×) from $4.6M in Q2 2026 to $256M in Q3 2026. Operating margin 69.2% against -919.0% (+988.2 pts).